Anand Kiran Parikh
Known title: President and CEOCIK: 0002111813
Anand Kiran Parikh's purchase track record
Anand Kiran Parikh has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/22/2026 | FTH | $55K | +43.5% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FTH | ▲ Buy | Open Market | 2,806 | $55K | 6/22/2026 | View on chart |
| FTH | ▲ Buy | Option Exercise | 45,252 | $52K | 6/22/2026 | View on chart |
| FTH | ▲ Buy | Option Exercise | 8,213 | $10K | 6/22/2026 | View on chart |
| FTH | ▼ Sell | Other | 761,428 | — | 6/15/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH)
William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.